Skip to main content
Contact Us
Subscribe
E-Edition
90°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
112.28
-0.23 (-0.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
The Short List: 3 Meme Stock Battlegrounds to Keep on Your Radar
March 06, 2024
Explore the ups and downs of 3 meme stocks: Imperial Petroleum, Novavax and MicroCloud, as they navigate market challenges and speculation.
Via
InvestorPlace
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
March 06, 2024
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
Via
InvestorPlace
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
March 04, 2024
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities.
Via
InvestorPlace
It’s Time! 3 Dodgy Pharma Stocks to Sell in February
March 04, 2024
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action.
Via
InvestorPlace
Cracking The Code: Understanding Analyst Reviews For BioNTech
February 20, 2024
Via
Benzinga
Key Takeaways From BioNTech Analyst Ratings
January 23, 2024
Via
Benzinga
P/E Ratio Insights for BioNTech
January 09, 2024
Via
Benzinga
5 Value Stocks In The Healthcare Sector
March 04, 2024
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
February 12, 2024
Via
Benzinga
3 Blue-Chip Stocks to Buy at a 52-Week Low in February
February 07, 2024
Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.
Via
InvestorPlace
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
3 Pharma Stocks to Sell in February Before They Crash and Burn
February 02, 2024
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn.
Via
InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Comparative Study: BioNTech And Industry Competitors In Biotechnology Industry
January 03, 2024
Via
Benzinga
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
January 27, 2024
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.
Via
InvestorPlace
Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday
January 23, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
How Is The Market Feeling About BioNTech?
December 26, 2023
Via
Benzinga
Understanding BioNTech's Position In Biotechnology Industry Compared To Competitors
December 20, 2023
Via
Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
January 17, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
BioNTech Prepares To Be Commercial Ready By 2025, Revenue Growth Expected To Return In 2025
January 09, 2024
On Tuesday, BioNTech SE (NASDAQ: BNTX) outlined priorities at the Annual J.P.
Via
Benzinga
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
January 07, 2024
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)...
Via
Talk Markets
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
5 Value Stocks To Watch In The Healthcare Sector
January 01, 2024
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
December 25, 2023
Via
Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.